Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 20,476 |
|
|||||
| News | - | ||||||
| Day High | 4.585 | Low High |
|||||
| Day Low | 4.32 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Aptorum Group Ltd | APM | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.21 | 4.90% | 4.50 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 4.32 | 4.32 | 4.585 | 4.50 | 4.29 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 173 | 20,476 | US$ 4.48 | US$ 91,804 | - | 1.35 - 17.49 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:01 | 7 | US$ 4.48 | USD |
Aptorum Group Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 18.77M | 4.17M | - | 431k | -2.83M | -0.68 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Aptorum News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.80 | 4.875 | 4.20 | 4.46 | 8,000 | -0.30 | -6.25% |
| 1 Month | 4.70 | 5.63 | 3.70 | 4.66 | 17,037 | -0.20 | -4.26% |
| 3 Months | 8.29 | 11.19 | 3.70 | 7.76 | 53,049 | -3.79 | -45.72% |
| 6 Months | 2.03 | 17.49 | 1.35 | 8.41 | 1,215,572 | 2.47 | 121.67% |
| 1 Year | 2.91 | 17.49 | 1.35 | 8.03 | 645,504 | 1.59 | 54.64% |
| 3 Years | 29.10 | 35.00 | 1.35 | 13.30 | 514,007 | -24.60 | -84.54% |
| 5 Years | 234.00 | 266.00 | 1.35 | 21.34 | 482,852 | -229.50 | -98.08% |
Aptorum Description
| Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. Its lead projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services. |
